The State of Weight-Loss Drugs
Motley Fool Money1 Maalis

The State of Weight-Loss Drugs

$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years. Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss: - How weight-loss drugs actually work, and how big-name prescriptions differ from each other. - What investors need to know about Ozempic and Mounjarno’s patent cliffs. - The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued. Companies discussed: LLY, NOVO, HIMS, PFE, RHHBY, VKTX, GPCR, ISRG Host: Ricky Mulvey Guest: Karl Thiel Producer: Mary Long Engineer: Rick Engdahl Learn more about your ad choices. Visit megaphone.fm/adchoices

Jaksot(2009)

Motley Fool Money: 03.27.2009

Motley Fool Money: 03.27.2009

A good week for the stock market, so is it time to pop the champagne? With stocks like Amazon, Netflix, Chipotle and Best Buy on the rise, is now the time to buy? And what does the panel think of Treasury Secretary Tim Geithner’s bank rescue plan? We tackle those questions, share some beefs, highlight a few stocks on our radar, and debate the relative merits of Eliot Spitzer and Britney Spears. Learn more about your ad choices. Visit megaphone.fm/adchoices

27 Maalis 200917min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
psykopodiaa-podcast
mimmit-sijoittaa
rss-rahapodi
kasvun-kipuja
pomojen-suusta
rss-myynti-ei-ole-kirosana
ostan-asuntoja-podcast
lakicast
rss-neuvottelija-sami-miettinen
pari-sanaa-lastensuojelusta
rss-lahtijat
rss-ainin-sekatoimisto
taloudellinen-mielenrauha
rahapuhetta
hyva-paha-johtaminen
rss-rahamania
rss-laakispodi
rss-bisnesta-bebeja
rss-kohti-unelmia